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Abstract Although paediatric patients frequently suffer from
intoxications with atypical antipsychotics, the number of stud-
ies in young children, which have assessed the effects of acute
exposure to this class of drugs, is very limited. The aim of this
study was to achieve a better characterization of the acute
toxicity profile in young children of the atypical antipsy-
chotics clozapine, olanzapine, quetiapine, and risperidone.
We performed a multicentre retrospective analysis of cases
with atypical antipsychotics intoxication in children younger
than 6 years, reported by physicians to German, Austrian, and
Swiss Poisons Centres for the 9-year period between January
1, 2001 and December 31, 2009. One hundred and six cases (31
clozapine, 29 olanzapine, 12 quetiapine, and 34 risperidone)
were available for analysis. Forty-seven of the children showed
minor, 28 moderate, and 2 severe symptoms. Twenty-nine cases
were asymptomatic. No fatalities were recorded. Symptoms
predominantly involved the central nervous and cardiovascular
systems. Minor reduction in vigilance (Glasgow Coma Scale
score >9) (62 %) was the most frequently reported symptom,
followed by miosis (12 %) and mild tachycardia (10 %). Extra-
pyramidal motor symptoms were observed in one case (1 %)
after ingestion of risperidone. In most cases, surveillance and
supportive care were sufficient to achieve a good outcome, and
all children made full recovery. Conclusions: Paediatric antipsy-
chotic exposure can result in significant poisoning; however, in
most cases only minor or moderate symptoms occurred and
were followed by complete recovery. Symptomatic patients
should be monitored for central nervous system depression
and an electrocardiogram should be obtained.
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Introduction
Accidental poisoning in children represents a significant cause
of paediatric morbidity [2,5,20]. According to the latest An-
nual Report of the American Association of Poison Control
Centres, children under the age of 6 years accounted for about
half of all human intoxications [5], which is comparable to the
situation in Switzerland (STIC Annual Report 2012). Addi-
tionally, most emergency department visits for intoxication in
children involved patients younger than 6 years [22,30]. De-
spite prevention efforts like introduction of child-resistant
packaging and parental education, paediatric medication poi-
soning and emergency department visits after medication
exposure are on the rise [4,6]. Particularly, the number of
poisoning with antipsychotic drugs increased remarkably in
recent years, with almost 8 % involving children younger than
6 years [13].
Atypical antipsychotics have become first-line drugs in the
treatment of schizophrenia and other common neuropsychiat-
ric disorders, such as anxiety disorders, bipolar disorders, tic
disorders, and obsessive compulsive disorders because of
improved efficacy and side effect profiles, including a lower
incidence of extrapyramidal side effects and tardive dyskine-
sia [7,8,12,24]. The use of this class of drugs in children and
adolescents is increasing, although frequently in an off-label
or unlicensed manner [1,12,14,16,18,21,27,35]. They current-
ly represent the most commonly prescribed antipsychotics for
young patients [21]. The main indications in children are
psychotic and several nonpsychotic conditions including at-
tention deficit hyperactivity disorder, autism, eating disorders,
tic disorders, and mental retardation associated with behav-
ioural or psychiatric disorders [9,23].
The increasing use made atypical antipsychotics more ac-
cessible to young children, which are in a stage of mouthing
unknown objects and therefore are especially susceptible to
poisoning [25]. Although antipsychotic poisoning has become
a significant cause of morbidity in children, the information
available in literature is limited to systematic reviews based on
paediatric therapeutic studies, case reports, isolated case se-
ries, expert opinions, or extrapolations from studies in adults.
The purpose of this study was to achieve a better charac-
terization of the acute toxicity profile in young children of four
common atypical antipsychotics. It should help to improve the
management of patients by increasing the amount of evidence
to aid risk estimation of accidental ingestion.
Methods
Data acquisition and study design
The study was designed as a multicentre retrospective descrip-
tive study of cases with atypical antipsychotics (clozapine,
olanzapine, quetiapine (immediate and extended release), and
risperidone) intoxication in children under 6 years of age.
These cases were reported between January 2001 and Decem-
ber 2009 to poisons centres in Austria (Vienna), Germany
(Berlin, Erfurt, Freiburg, Göttingen, Mainz), and Switzerland
(Zurich), according to the Codex of the Society of Clinical
Toxicology (GfKT) [32]. The centres were asked to provide
the anonymized data in a standardized exchange spreadsheet
format [31]. This data, entered by physicians, included age,
sex, weight, ingested drug and dose, symptoms/signs/labora-
tory values and causal relationship, severity of intoxication,
decontamination measures, latency to decontamination, and
therapeutic interventions. The first author reviewed all cases
in detail before they were entered into the study to ensure that
they fulfil the inclusion criteria. Doubts were resolved by
consensus in an expert panel including a senior clinical toxi-
cologist and a clinical pharmacologist with additional qualifi-
cations in general internal medicine.
Since not all centres classify severity of symptoms in the
same way, the cases were also re-evaluated according to the
Poisoning Severity Score (PSS) [28], developed by the Euro-
pean Association of Poison Centres and Clinical Toxicolo-
gists, the International Programme on Chemical Safety, and
the European Commission.
Ethical approval was obtained from the ethics com-
mittees of the participating Poisons Centres, and the
study has therefore been performed in accordance with
ethical standards.
Inclusion criteria
For the reported cases, the following criteria had to be fulfilled
to be included in the study:
– Monointoxication with either clozapine, olanzapine,
quetiapine (immediate and extended release), or
risperidone
– Patient age < 6 years
– Follow-up, reported by the treating physician
– Ingested dose known (no dose range was accepted);
regardless of dose, accidental ingestion of one of the
drugs of interest was considered an overdose
– Confirmed or likely causal relationship between exposure
and clinical effect; causality assessment was based on a
clear temporal relationship between drug ingestion and
symptoms, absence of other drugs or diseases that can
explain the symptoms, and the presence of symptoms that
are described for the drug in question or are plausible
from a pharmacodynamic point of view; since these
criteria could not be used for asymptomatic patients, these
cases were judged according to the ingested dose reported
by parents or caregivers
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Data classification
According to the Poisoning Severity Score [28], the severity
of symptoms of individual patients was classified as follows:
– ‘Minor’ if only mild, transient, and spontaneously resolv-
ing symptoms were present
– ‘Moderate’ if at least one pronounced or prolonged symp-
tom was recorded
– ‘Severe’ if at least one severe or life-threatening symptom
was observed
The reported symptoms and signs according to their sever-
ity are shown in Table 1.
Statistical evaluation
The statistical analysis was performed using the software
package R [29]. Descriptive statistics were used to analyse
the data. Correlation between age of patients and number of
ingested pills was tested by Spearman rank correlation test.
The Wilcoxon test was used to analyse the association be-
tween gender and ingested dose, and the difference between
recorded and estimated body weight. Statistical significance
was defined as p<0.05.
Results
During the study period, data of 106 children fulfilling inclu-
sion criteria were available for analysis: in 34 (32%) cases, the
involved atypical antipsychotic was risperidone, in 31 (29 %)
clozapine, in 29 (27 %) olanzapine, and in 12 (11 %)
quetiapine (all of them had immediate-release tablet
formulation).
Because of the partially incomplete body weight data, in
some cases weight had to be estimated using World Health
Organization (WHO) growth standard charts [34]. There was
no significant difference between recorded and estimated
weight (Wilcoxon test p=0.08).
Baseline characteristics of the patients are summarized in
Table 2. There were 43 (41 %) females, 52 (49 %) males, and
in 11 (10 %) cases gender was not reported. The mean age of
the patients was 2.6 years (range 0.8−5.5 years; median
2.3 years). No correlation between age and number of
ingested pills was found (Spearman correlation coefficient,
0.16; 95 % CI, −0.05 to 0.36).
The number of ingested pills ranged from 0.25 to 8, and 1
pill was ingested in almost half of intoxications (49; 46 %),
followed by 0.5 (15; 14%), and 2 (13; 12%). Only nine (9 %)
children ingested more than two pills. Concerning the number
of ingested pills, there was no significant difference between
males and females (Wilcoxon test, p=0.39).
Neurological and cardiovascular symptoms were
predominating. Minor reduction in vigilance (Glasgow Coma
Scale score >9) (66; 62 %) was the most frequently reported
symptom, followed by miosis (13; 12 %) and tachycardia
(>140 to <160 bpm) (11; 10 %).
There were 71 (67 %) presentations with an admission
Glasgow Coma Scale (GCS) score of <15: in 66 (62 %) cases,
GCSwas >9 (1GCS 11–13; 1 GCS 12; 1 GCS 13 and 63GCS
>9 with no further subdivision), in 4 cases (4 %), GCS was 8–
9 and in 1 (1 %) GCS was ≤7 (GCS 6). Extrapyramidal
adverse effects were observed in one girl of 2.8 years after
ingestion of 2 mg (0.1 mg/kg) of risperidone. No extrapyra-
midal motor symptoms were recorded after the ingestion of
clozapine, olanzapine, or quetiapine. Electrocardiography was
performed in 32 (30 %) children: three (3 %) showed extra-
systoles, and in one (1 %) previously healthy girl aged
1.6 years with potassium value of 3.6 mmol/l, a prolonged
Table 1 Symptoms and severity of intoxication in the study population
Minor Moderate Severe
Cardiovascular system Tachycardia (HR >140 to <160 bpm),
extrasystoles, hypertension
(systolic blood pressure 121–139 mmHg)
Tachycardia (HR 160–190 bpm),
bradycardia (HR 60–80 bpm),
prolonged QTc interval
(QTc interval < 10 % longer than
the upper norm value of 450 ms)
Tachycardia (HR >190 bpm)
Gastrointestinal tract Abdominal pain, vomiting
Metabolism Hypokalemia (K 3.0–3.4 mmol/l)
Nervous system Minor reduction in vigilance (GCS >9),
ataxia, mild cholinergic/anticholinergic
symptoms (e.g. miosis, sialorrhea),
EPS, headache, restlessness
Unconsciousness with appropriate
response to pain (GCS 8–9),
confusion, disorientation,
dysarthria, hyporeflexia,
myoclonia
Deep coma with inappropriate
response to pain or unresponsive
to pain (GCS ≤7)
Respiratory system Arterial oxygen saturation
<85 %, dyspnoea
EPS extrapyramidal side effects, GCSGlasgow Coma Scale, HR heart rate, bpm beats per minute, QTcQT interval corrected for heart rate
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QTc interval (Bazett correction formula) of 468 ms with heart
rate of 136 bpm was recorded after ingestion of 150 mg
(13.6 mg/kg) of quetiapine. The observed symptoms and signs
are summarized in Table 3. Gastrointestinal decontamination
with activated charcoal was performed in 49 (46 %) children,
in 32 (30 %) of these within 1 h of ingestion. Gastric lavage
was performed in one case and one case of vomiting induced
by parents was reported.
The overall toxicity was rated as severe in 2 (2 %), mod-
erate in 28 (26 %), and minor in 47 (44 %) cases according to
the PSS. Twenty-nine (27 %) children were asymptomatic
(Table 4). No fatalities were recorded.
The toxic dose per kilogram body weight was estimated as
the lowest dose causing objective symptoms or signs. For
clozapine, the toxic dose was 0.8 mg/kg, resulting in restless-
ness, ataxia, dysarthria, and somnolence; for olanzapine,
0.4 mg/kg, resulting in ataxia and somnolence; for quetiapine,
3.1 mg/kg, resulting in ataxia and somnolence; for risperi-
done, 0.05 mg/kg, resulting in somnolence and mild
tachycardia.
The management of atypical antipsychotic toxicity mainly
consisted of surveillance (64 cases; 60 %), cardiovascular and
respiratory monitoring (10; 10 %), supportive care with intra-
venous fluids (2; 2 %), potassium substitution (2; 2 %), ad-
ministration of oxygen (1; 1 %), administration of benzodiaz-
epines in case of agitation or tachycardia (2; 2 %), and admin-
istration of biperiden in the one case with extrapyramidal side
effects (1; 1 %). All children showed complete recovery.
Discussion
This study investigated symptoms, signs, and severity of
clozapine, olanzapine, quetiapine, and risperidone intoxica-
tion in children under the age of 6 years. Consistent with the
literature, we found a peak incidence of intoxications in 2-
year-old toddlers [5,6,30].
Neither a correlation between age and quantity of ingested
pills nor a clear imbalance between gender and occurrence of
intoxication was found. Last mentioned is in contrast to pre-
vious studies, reporting a clear male predominance in child-
hood poisoning [4,5].
Our results demonstrate that accidental poisoning with
atypical antipsychotics in children under the age of 6 years,
who in the majority of cases ingested 0.5 to 2 pills, predom-
inantly showed a benign clinical course with no sequelae. This
finding is in accordance with previous reports [7,36]. Al-
though a significant number of patients remained asymptom-
atic, significant toxicity after ingestion of a single tablet of this
class of drugs has been described [7,20], and susceptibility for
serious toxic effects in children has been postulated [7,10].
However, it has to be acknowledged that the reporting of cases
with severe symptoms after ingestion of low doses (i.e. pub-
lication bias) may be an issue which might lead to an overes-
timation of toxicity on the basis of literature data.
Atypical antipsychotic intoxication in children showed the
same clinical course as observed in adolescents and adults,
with neurological and cardiovascular symptoms
predominating [3,7,9,24]. The toxic dose per kilogram body
weight found in this study for olanzapine is similar to that
described by Isbister et al. [20]. In contrast, for clozapine we
found a much lower toxic dose compared to Isbister et al.,
which suggests a higher toxicity of this drug in overdose. To
our knowledge, no toxic doses for quetiapine and risperidone
have been described previously.
The central nervous system effects were the most common
manifestations and ranged from somnolence, apathy, and dys-
arthria in mild poisoning, to deep coma in severe intoxication
[7]. In contrast to adults, in which central anticholinergic
syndrome has been described for quetiapine, no children with
such condition were observed in our study [15]. The fact that
Table 2 Patients’ baseline characteristics
Total Clozapine Olanzapine Quetiapine Risperidone
Patients n (%) 106 (100) 31 (29) 29 (27) 12 (11) 34 (32)
Sex
Female/male/unknown 43:52:11 14:13:4 11:15:3 4:6:2 14:18:2
Age (years)
Mean 2.6 2.3 2.5 2.7 2.7
Median, range 2.3, 0.8–5.5 2, 0.8–5.1 2.1, 0.9–5 2.8, 1.6–5.5 2.5, 1.2–5.5
Decontamination (%)
Total 49 (46)
Within 1 h 32 (30) 11 (36) 10 (35) 3 (25) 8 (24)
>1 h/No decontamination 70 (66) 18 (58) 19 (66) 8 (67) 25 (74)
Unknown 4 (4) 2 (7) – 1 (8) 1 (3)
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somnolence was the most common symptom is not surprising,
since somnolence is already a frequently observed adverse
effect in the therapeutic dose range [8,9,12,27]. In accordance
with previous reports, clozapine seems to be the most sedative
substance [8,27].
Compared with first-generation antipsychotic drugs, acute
extrapyramidal symptoms (EPS) are less frequent with atyp-
ical antipsychotic drugs [18,21,35], but seem to occur more
often in children than in adults [12,17,21]. They typically
manifest as akathisia, parkinsonism, or dystonic reactions.
EPS were frequently reported after poisoning with risperidone
[26], particularly in children [7,20]. In this study, only one
case of EPS resulting from risperidone poisoning was report-
ed. No EPS were observed after exposure to clozapine,
olanzapine, and quetiapine, which seem to have a more
favourable EPS profile [7,8].
Cardiovascular toxicity is also an uncommon finding in
atypical antipsychotic poisoning compared to intoxication
with first-generation antipsychotics [7,33]. Main cardiovascu-
lar manifestations are tachycardia, hypotension, and prolon-
gation of the QT interval [33], which are largely an extension
Table 4 Severity of intoxication and ingested dose
Number of cases (%) Dose range (mg/kg),
mean±SD
Total
No symptoms 29 (27 %)
Minor 47 (44 %)
Moderate 28 (26 %)
Severe 2 (2 %)
Clozapine
No symptoms 2 (7 %) 1.3–2.5, 1.9±0.8
Minor 19 (61 %) 0.8–16.7, 7.2±3.6
Moderate 10 (32 %) 3.6–33.3, 10.3±8.8
Severe –
Olanzapine
No symptoms 6 (21 %) 0.2–1.4, 0.8±0.5
Minor 11 (38 %) 0.4–3.1, 1.4±1.1
Moderate 11 (38 %) 0.5–3.8, 1.6±1.0
Severe 1 (4 %) 4.2
Quetiapine
No symptoms 6 (50 %) 1.1–14.3, 4.7±4.9
Minor 4 (33 %) 3.1–13.6, 6.6±4.7
Moderate 2 (8 %) 13.3–25, 19.2±8.3
Severe –
Risperidone
No symptoms 15 (44 %) 0.03–1.5, 0.2±1.2
Minor 13 (38 %) 0.05–1.3, 0.3±0.3
Moderate 5 (15 %) 0.2–0.5, 0.3±0.1
Severe 1 (3 %) 0.2
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of pharmacological effects. In accordance with the literature
[12,24] and observations in the therapeutic dose range, tachy-
cardia was the most common cardiovascular symptom in
overdose. Although intoxication with atypical antipsychotics
has been reported to be associated with ECG changes and also
QT prolongation with the inherent risk of torsades de pointes
[33,35], only minor ECG changes were recorded in this study,
with a single case of moderate prolongation of the QTc inter-
val in a previously healthy child after exposure to quetiapine,
which is probably due to overestimation of the QT by Bazett
correction because of tachycardia [11]. This confirms the
rarity of serious cardiovascular effects in atypical antipsychot-
ic poisoning.
Gastrointestinal decontamination with activated charcoal
was performed within 1 h of ingestion in every third child.
Unfortunately, no analysis of the effect of gastrointestinal
decontamination on the severity of the intoxication could be
performed because of low case numbers, heterogeneity of the
study population, and absence of a control group.
Conclusions
We demonstrated that the majority of children poisoned with
the atypical antipsychotic drugs clozapine, olanzapine,
quetiapine, and risperidone had a benign clinical course.
Symptoms predominantly involved the central nervous and
cardiovascular systems. Extrapyramidal side effects were rare,
and the only case reported was caused by risperidone intoxi-
cation. We identified toxic doses of the four investigated
substances, and this may be helpful for the clinician for risk
estimation after accidental ingestion. We recommend to mon-
itor symptomatic patients for central nervous system depres-
sion and to obtain an electrocardiogram with a focus on
rhythm disturbances and ECG intervals.
Study limitations
This study has a number of limitations, which are primarily
related to the retrospective nature of the study design and the
relatively small sample size. Last mentioned is mainly due to
our strict inclusion criteria, in particular, the decision to only
include monointoxications and cases with well-defined
ingested doses, which we are convinced were necessary to
be able to interpret the findings properly, in particular, because
in most cases we were not able to obtain plasma concentra-
tions of the investigated substances to confirm the ingested
amount.
Larger multicentre series of atypical antipsychotic poison-
ing in children have, however, not been published to date.
Furthermore, it is likely that not all cases which occurred in
the referral population were reported to involved poisons
centres and that bias toward reporting of the more severe cases
occurred. Data are also partially incomplete, which is the
nature of retrospective studies using poison centre data [19].
The use of population data to substitute for missing body
weight data is a clear, but unavoidable, limitation.
Furthermore, the quantities of ingested drugs are estimates
derived from the best information provided by the family
member or caregiver and may over- or underestimate the
actual ingestion.
Since the majority of our patients ingested low doses of the
investigated antipsychotics, the findings cannot be extended
to children with larger overdoses.
Conflict of interest The authors declare that they have no conflict of
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